Medy-Tox Inc. (086900.KQ)

Medy-Tox Inc. (086900.KQ) — VMCI valuation read

Headline read on 086900.KQ: VMCI of 54/100 versus a Healthcare sector median of 50. The 4-point above-median position is what makes Medy-Tox Inc. a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 086900.KQ: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 086900.KQ: value (086900.KQ trades at 19.0x earnings, 6% above the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 1.3x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

086900.KQ fell 1.1% over the trailing 7 days, with a -10.0% read on a 30-day basis.